Key result
M3 muscarinic receptor activation confers cardioprotective effects against arrhythmia, hypertrophy, and fibrosis.
Why the study?
Growing evidence links M3-mAChR to cardiovascular diseases with cardioprotective effects, warranting a summary of its expression patterns, functions, and mechanisms.
Does M3-mAChR activation improve cardioprotection in cardiovascular diseases?
Does M3-mAChR activation improve cardioprotection in cardiovascular diseases?
Answers are grounded in this paper and cite their sources.
M3-mAChR represents a promising diagnostic and therapeutic target for cardiovascular diseases due to its wide range of cardioprotective mechanisms.
The muscarinic acetylcholine receptor M3 (M3-mAChR) is involved in various physiological and pathological processes. Owing to specific cardioprotective effects, M3-mAChR is an ideal diagnostic and therapeutic biomarker for cardiovascular diseases (CVDs). Growing evidence has linked M3-mAChR to the development of multiple CVDs, in which it plays a role in cardiac protection such as anti-arrhythmia, anti-hypertrophy, and anti-fibrosis. This review summarizes M3-mAChR’s expression patterns, functions, and underlying mechanisms of action in CVDs, especially in ischemia/reperfusion injury, cardiac hypertrophy, and heart failure, opening up a new research direction for the treatment of CVDs.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2024) conducted a review in Cardiovascular diseases (ischemia/reperfusion injury, cardiac hypertrophy, and heart failure). Muscarinic acetylcholine receptor M3 (M3-mAChR) activation was evaluated. Activation of the muscarinic acetylcholine receptor M3 exerts cardioprotective effects, including anti-arrhythmia, anti-hypertrophy, and anti-fibrosis properties across various cardiovascular diseases.
Synapse has enriched 10 related papers. Consider them for comparative context: